Related Experiment Video
Updated: Jul 3, 2025
03:50
Acupoint Application Combined with Acupoint Massage for Treating Constipation in a Patient with Chronic Obstructive Pulmonary Disease
Published on: August 18, 2023
1.8K
Potential drug-induced constipation: A retrospective study using a Japanese claims database
Yusuke Karasawa1, Kazutaka Nozawa1, Atsushi Nakajima2
1Medical Affairs, Viatris Pharmaceuticals Japan Inc. Tokyo Japan.
JGH Open : an Open Access Journal of Gastroenterology and Hepatology
|February 16, 2024
Summary
Drug-induced constipation (DIC) affects about 11% of patients with constipation. Cardiovascular drugs are common culprits. Recognizing DIC is crucial for effective patient treatment.
Area of Science:
- Pharmacovigilance
- Gastroenterology
- Real-world evidence
Background:
- Detailed clinical information on drug-induced constipation (DIC) is limited.
- This study investigated the real-world prevalence and characteristics of DIC.
Purpose of the Study:
- To determine the proportion of potential drug-induced constipation (pDIC) in a real-world setting.
- To identify causative drugs and associated factors for pDIC.
Main Methods:
- Retrospective analysis of a Japanese claims database (2014-2021).
- Propensity score matching of constipation and non-constipation cohorts with known causative drugs (CDs).
- Logistic regression to identify associated factors for pDIC.
Main Results:
- Potential DIC (pDIC) accounted for 10.9% of treated constipation cases.
- Cardiovascular drugs were the most frequently prescribed causative drugs (47.9%).
- Male sex, specific comorbidities, and all CD classes were associated with pDIC.
Conclusions:
- Approximately 11% of constipation cases may be drug-induced.
- Physicians must be aware of DIC to optimize treatment strategies, differentiating it from other constipation types.
Related Concept Videos
01:21Drugs for Treatment of Constipation-Predominant IBS
164
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
164
01:17Drugs for Treatment of Diarrhea-Predominant IBS
170
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
170
01:23Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
252
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
252
01:19Pharmacovigilance
833
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
833
01:20Drugs Affecting GI Tract Motility: Other Laxatives
217
Laxatives are primarily used to alleviate constipation, a common gastrointestinal disorder characterized by infrequent bowel movements and difficulty passing stools. They work by various mechanisms to increase the volume or frequency of bowel movements. The primary modes of action of laxatives include increasing stool bulk, softening the stool, stimulating intestinal motility, and osmotically drawing water into the intestines.
Osmotic or saline laxatives, like magnesium hydroxide or milk of...
Osmotic or saline laxatives, like magnesium hydroxide or milk of...
217
01:17Drugs Affecting GI Tract Motility: Opioids as Antidiarrheal Agents
199
Diarrhea, a condition marked by frequent loose or watery bowel movements, can be triggered by multiple factors such as viral or bacterial infections, food intolerances, anxiety, medications, and digestive disorders. Symptoms may include abdominal pain, bloating, nausea, and cramping. Severe or prolonged diarrhea can lead to complications like electrolyte imbalances, malnutrition, and dehydration if left untreated.
Opioids, widely used antidiarrheal agents, mitigate diarrhea by slowing down...
Opioids, widely used antidiarrheal agents, mitigate diarrhea by slowing down...
199